Expand BCRX Menu
BCRX MENU

BCRX Latest Press Releases

-- May 13, 2024 --

ORLADEYO (berotralstat) Approved in Mexico Globe Newswire 7:00 AM

-- May 9, 2024 --

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat) Globe Newswire 7:00 AM

-- May 7, 2024 --

BioCryst to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 6, 2024 --

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- May 3, 2024 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- April 22, 2024 --

BioCryst to Report First Quarter 2024 Financial Results on May 6 Globe Newswire 7:00 AM

-- April 17, 2024 --

BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Globe Newswire 4:30 AM

-- April 3, 2024 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- March 25, 2024 --

BioCryst to Present at Upcoming Investor Conferences Globe Newswire 4:01 PM

-- March 5, 2024 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- February 26, 2024 --

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones Globe Newswire 7:00 AM

-- February 23, 2024 --

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment Globe Newswire 7:00 AM

-- February 21, 2024 --

BioCryst to Present at Upcoming Investor Conferences Globe Newswire 4:01 PM

-- February 19, 2024 --

BioCryst Launches ORLADEYO (berotralstat) in Italy Globe Newswire 7:54 AM

-- February 12, 2024 --

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 Globe Newswire 7:00 AM

-- February 5, 2024 --

BioCryst to Present New ORLADEYO (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting Globe Newswire 7:00 AM

-- February 2, 2024 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- January 5, 2024 --

BioCryst Announces Preliminary Full Year 2023 ORLADEYO (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability Globe Newswire 4:01 PM

-- January 3, 2024 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:02 PM
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 19, 2023 --

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO (berotralstat) Globe Newswire 7:00 AM